Topical endocannabinoid for atopic dermatitis
Study suggests that a newly developed topical endocannabinoid membrane transporter inhibitor can minimized allergic flares and pruritus in dogs with atopic dermatitis.
A study aimed to test the effects of a 1% solution of a topical endocannabinoid membrane transporter inhibitor on pruritus and dermatitis in atopic dermatitis. Nineteen Beagles that had confirmed allergy to dust mites were given treatment twice a day and evaluated twice weekly for 28 days. Significant decrease on pruritus with treatment and no adverse effects were noted.
Read more by clicking on the link below:
